Zymeworks is a biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates.
Company profile
Ticker
ZYME
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Zymeworks Delaware Inc.
SEC CIK
Corporate docs
Subsidiaries
Zymeworks CallCo ULC • Zymeworks ExchangeCo Ltd. • Zymeworks BC Inc. • Zymeworks Management Inc. • Zymeworks Biopharmaceuticals Inc. • Zymeworks Pharmaceuticals Limited • Zymeworks Lifesciences Pte. Ltd. ...
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
1 Apr 24
8-K
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
28 Mar 24
S-3ASR
Automatic shelf registration
7 Mar 24
RW
Registration withdrawal request
7 Mar 24
S-8
Registration of securities for employees
6 Mar 24
S-3
Shelf registration
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
6 Mar 24
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-K
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
8 Feb 24
Latest ownership filings
4
Neil Gallagher
2 Apr 24
3
Neil Gallagher
2 Apr 24
3
Scott Platshon
4 Mar 24
SC 13D
EcoR1 Capital, LLC
22 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
4
Alessandra Cesano
9 Feb 24
3
Alessandra Cesano
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 94.33 mm | 94.33 mm | 94.33 mm | 94.33 mm | 94.33 mm | 94.33 mm |
Cash burn (monthly) | 15.92 mm | 145.83 k | 11.08 mm | (no burn) | 409.33 k | 7.22 mm |
Cash used (since last report) | 109.60 mm | 1.00 mm | 76.26 mm | n/a | 2.82 mm | 49.73 mm |
Cash remaining | -15.27 mm | 93.33 mm | 18.07 mm | n/a | 91.51 mm | 44.60 mm |
Runway (months of cash) | -1.0 | 640.0 | 1.6 | n/a | 223.6 | 6.2 |
Institutional ownership, Q3 2023
91.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 139 |
Opened positions | 22 |
Closed positions | 23 |
Increased positions | 48 |
Reduced positions | 39 |
13F shares | Current |
---|---|
Total value | 391.10 bn |
Total shares | 64.76 mm |
Total puts | 68.50 k |
Total calls | 51.20 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
EcoR1 Capital | 13.44 mm | $85.19 bn |
BVF | 5.87 mm | $37.22 bn |
Redmile | 5.66 mm | $35.89 bn |
MS Morgan Stanley | 4.48 mm | $28.43 bn |
BLK Blackrock | 3.62 mm | $22.94 bn |
All Blue Falcons FZE | 2.79 mm | $24.39 mm |
Rubric Capital Management | 2.65 mm | $16.81 bn |
Credit Suisse | 2.49 mm | $15.88 bn |
Vanguard | 2.38 mm | $15.11 bn |
Farallon Capital Management | 2.00 mm | $12.68 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Neil Gallagher | Stock Option Common Stock | Grant | Acquire A | No | No | 9.23 | 74,000 | 683.02 k | 74,000 |
8 Feb 24 | Alessandra Cesano | Stock Option Common Stock | Grant | Acquire A | No | No | 11.47 | 74,000 | 848.78 k | 74,000 |
News
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
8 Apr 24
Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $14
12 Mar 24
HC Wainwright & Co. Maintains Neutral on Zymeworks, Raises Price Target to $10
11 Mar 24
Zymeworks Q4 Adj EPS $(0.16) Beats $(0.43) Estimate
6 Mar 24
Earnings Scheduled For March 6, 2024
6 Mar 24
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
24 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
20 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
16 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
12 Apr 24
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
11 Apr 24